Amendment to the specification

Please replace paragraph 002 as follows

Marked-up version:
[0002] The subject matter of this application is related to application Ser. No. 09/858,210 filed May 15, 2001, entitled Method and System for Colloid Exchange Therapy filed by David Radunsky et al., now U.S. Pat. No. 6,787,040; and application Ser. No. 09/912,904 filed Jul. 25, 2001, entitled Hemofiltration Systems, Methods and Devices Used to Treat Inflammatory Mediator Related Disease filed by James R. Matson et al. now U.S. Pat. No. 6,730,266.

Clean version:
[0002] The subject matter of this application is related to application Ser. No. 09/858,210 filed May 15, 2001, entitled Method and System for Colloid Exchange Therapy filed by David Radunsky et al., now U.S. Pat. No. 6,787,040; and application Ser. No. 09/912,904 filed Jul. 25, 2001, entitled Hemofiltration Systems, Methods and Devices Used to Treat Inflammatory Mediator Related Disease filed by James R. Matson et al. now U.S. Pat. No. 6,730,266.

Amendments to Claims
This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-15. (canceled)

16. (currently amended) A hemofiltration system for treating an inflammatory mediator related disease of a mammal, the system comprising:

a first conduit adapted to direct a blood stream from the mammal to a hemofilter, the hemofilter adapted to remove an ultrafiltrate from the blood stream so as to create a filtered

blood stream and an ultrafiltrate stream, the hemofilter having a molecular weight exclusion limit of greater than or equal to 69,000 Daltons;

a second conduit adapted to direct the filtered blood stream from the hemofilter back to the mammal;

a third conduit adapted to direct the ultrafiltrate stream from the hemofilter to an adsorptive device,

the adsorptive device adapted to receive the ultrafiltrate stream, to contact the ultrafiltrate stream with an adsorbent material, and to output a post adsorption ultrafiltrate stream after ~~selectively~~ removing at least one inflammatory mediator; and

a fourth conduit adapted to receive the post adsorption ultrafiltrate stream from the adsorptive device and to direct the post adsorption ultrafiltrate back to the mammal.

17. (previously presented) A hemofiltration system according to Claim 16 wherein the fourth conduit merges with the second conduit so as to combine at least a portion of the post adsorption ultrafiltrate stream with the filtered blood stream to thereby return a combined stream to the mammal.

18 (new) A hemofiltration system according to Claim 16, wherein the hemofilter is operable to sieve albumin to the ultrafiltration stream.

19. (new) A hemofiltration system according to Claim 16, further comprising a fifth conduit adapted to divider for splitting the ultrafiltrate stream and into a waste stream and a return stream.

20. (new) A hemofiltration system according to Claim 19, further comprising a waste container.

21. (new) A hemofiltration system according to Claim 19, wherein the divider is a three-way joint.

22. (new) A hemofiltration system according to Claim 16, wherein the hemofilter

comprises a material selected from the group of polysulfone, polyacrylonitrile, polymethylmethacrylate, polyvinyl-alcohol, polyamide, polycarbonate, and cellulose derivatives.

23. (new) A hemofiltration system of Claim 16, wherein the adsorbent material is selected from a group consisting of activated charcoal, uncharged resins, charged resins, silica, immobilized polymyxin B, anion exchange resin, cation exchange resin, neutral exchange resin, polysulfone, polyacrylonitrile, polymethylmethacrylate, polyvinyl-alcohol, polyamide, polycarbonate, cellulose derivatives, immobilized monoclonal antibodies, immobilized IM receptors, immobilized specific antagonists, and any combination thereof.

24. (new) A hemofiltration system of Claim 16, wherein the adsorbent material is comprised of adsorbent resins selected from a group consisting of immobilized polymyxin B , polystyrene-derivative fibers, cation exchange resins, neutral exchange resins, anion exchange resins, cellulose materials, polysulfone, polyacrylonitrile, polymethylmethacrylate, polyvinyl-alcohol, polyamide, polycarbonate, cellulose derivatives, specific antibody coated materials, specific antagonist coated materials, and any combination thereof.